Ronald Hunt - Net Worth and Insider Trading

Ronald Hunt Net Worth

The estimated net worth of Ronald Hunt is at least $77 Million dollars as of 2024-11-10. Ronald Hunt is the Former 10% beneficial owner of Relypsa Inc and owns about 2,114,890 shares of Relypsa Inc (RLYP) stock worth over $68 Million. Ronald Hunt is the Director, 10% Owner of Harpoon Therapeutics Inc and owns about 224,284 shares of Harpoon Therapeutics Inc (HARP) stock worth over $5 Million. Ronald Hunt is also the Director of Rallybio Corp and owns about 4,449,360 shares of Rallybio Corp (RLYB) stock worth over $4 Million. Besides these, Ronald Hunt also holds Iterum Therapeutics PLC (ITRM) . Details can be seen in Ronald Hunt's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Ronald Hunt has not made any transactions after 2021-08-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Ronald Hunt

To

Ronald Hunt Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ronald Hunt owns 12 companies in total, including Iterum Therapeutics PLC (ITRM) , Harpoon Therapeutics Inc (HARP) , and Neuronetics Inc (STIM) among others .

Click here to see the complete history of Ronald Hunt’s form 4 insider trades.

Insider Ownership Summary of Ronald Hunt

Ticker Comapny Transaction Date Type of Owner
ITRM Iterum Therapeutics PLC 2019-06-13 director & 10 percent owner
HARP Harpoon Therapeutics Inc 2021-01-11 director & 10 percent owner
STIM Neuronetics Inc 2018-06-27 director & 10 percent owner
LIMIT LIMIT 2016-10-19 10 percent owner
LIMIT LIMIT 2012-12-18 10 percent owner
LIMIT LIMIT 2014-03-20 10 percent owner
LIMIT LIMIT 2013-04-10 10 percent owner
LIMIT LIMIT 2014-02-12 10 percent owner
LIMIT LIMIT 2013-11-27 other: Former 10% Beneficial Owner
LIMIT LIMIT 2013-11-20 director & other: Former 10% beneficial owner
LIMIT LIMIT 2011-07-13 10 percent owner
LIMIT LIMIT 2021-08-02 director

Ronald Hunt Latest Holdings Summary

Ronald Hunt currently owns a total of 4 stocks. Among these stocks, Ronald Hunt owns 2,114,890 shares of Relypsa Inc (RLYP) as of November 20, 2013, with a value of $68 Million and a weighting of 87.41%. Ronald Hunt owns 224,284 shares of Harpoon Therapeutics Inc (HARP) as of January 11, 2021, with a value of $5 Million and a weighting of 6.67%. Ronald Hunt also owns 4,449,360 shares of Rallybio Corp (RLYB) as of August 2, 2021, with a value of $4 Million and a weighting of 5.75%. The other 1 stocks Iterum Therapeutics PLC (ITRM) have a combined weighting of 0.17% among all his current holdings.

Latest Holdings of Ronald Hunt

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
RLYP Relypsa Inc 2013-11-20 2,114,890 31.99 67,655,331
HARP Harpoon Therapeutics Inc 2021-01-11 224,284 23.01 5,160,775
RLYB Rallybio Corp 2021-08-02 4,449,360 1.00 4,449,360
ITRM Iterum Therapeutics PLC 2018-05-30 97,087 1.39 134,951

Holding Weightings of Ronald Hunt


Ronald Hunt Form 4 Trading Tracker

According to the SEC Form 4 filings, Ronald Hunt has made a total of 0 transactions in Relypsa Inc (RLYP) over the past 5 years. The most-recent trade in Relypsa Inc is the acquisition of 185,978 shares on November 20, 2013, which cost Ronald Hunt around $2 Million.

According to the SEC Form 4 filings, Ronald Hunt has made a total of 1 transactions in Harpoon Therapeutics Inc (HARP) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Harpoon Therapeutics Inc is the acquisition of 23,529 shares on January 11, 2021, which cost Ronald Hunt around $4 Million.

According to the SEC Form 4 filings, Ronald Hunt has made a total of 1 transactions in Rallybio Corp (RLYB) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Rallybio Corp is the acquisition of 307,692 shares on August 2, 2021, which cost Ronald Hunt around $4 Million.

More details on Ronald Hunt's insider transactions can be found in the Insider Trading History of Ronald Hunt table.

Insider Trading History of Ronald Hunt

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ronald Hunt Trading Performance

GuruFocus tracks the stock performance after each of Ronald Hunt's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ronald Hunt is 38.96%. GuruFocus also compares Ronald Hunt's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ronald Hunt within 3 months outperforms 2 times out of 5 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Ronald Hunt's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Ronald Hunt

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
2 out of 5 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 9.17 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 7.17 LIMIT LIMIT LIMIT LIMIT LIMIT

Ronald Hunt Ownership Network

Ownership Network List of Ronald Hunt

No Data

Ownership Network Relation of Ronald Hunt

Insider Network Chart

Ronald Hunt Owned Company Details

What does Iterum Therapeutics PLC do?

Who are the key executives at Iterum Therapeutics PLC?

Ronald Hunt is the director & 10 percent owner of Iterum Therapeutics PLC. Other key executives at Iterum Therapeutics PLC include Chief Scientific Officer Michael W. Dunne , director & President & CEO Fishman Corey N. , and Chief Medical Officer Sailaja Puttagunta .

Iterum Therapeutics PLC (ITRM) Insider Trades Summary

Over the past 18 months, Ronald Hunt made no insider transaction in Iterum Therapeutics PLC (ITRM). Other recent insider transactions involving Iterum Therapeutics PLC (ITRM) include a net purchase of 55,000 shares made by Michael W. Dunne , and a net purchase of 10,000 shares made by Fishman Corey N. .

In summary, during the past 3 months, insiders sold 0 shares of Iterum Therapeutics PLC (ITRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Iterum Therapeutics PLC (ITRM) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 65,000 shares.

Iterum Therapeutics PLC (ITRM)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Iterum Therapeutics PLC Insider Transactions

No Available Data

Ronald Hunt Mailing Address

Above is the net worth, insider trading, and ownership report for Ronald Hunt. You might contact Ronald Hunt via mailing address: C/o Credit Suisse 1st Boston Prv Eqy, 11 Madison Avenue, New York Ny 10010.